Involvement of the endocannabinoid system in current and recurrent periodontitis: A human study

Abstract

AbstractObjectiveThe aim of the present study was to assess if the endocannabinoid system is involved differently in patients with recurrent and non‐recurrent periodontal disease and if in sites that have a predisposition for reactivation, levels of anandamide (AEA) change after periodontal therapy.BackgroundPeriodontal disease (PD) may be due to a dysregulation of the endocannabinoid system.MethodsPeriodontal patients were recruited, treated for PD and monitored. Gingival samples from these patients with recurrent (n = 10) and non‐recurrent (n = 10) periodontal disease were harvested before and after treatment and compared to those of periodontally healthy (n = 10) subjects. Levels of CB1 and CB2, AEA and CBs receptor activation were assessed in healthy and inflamed samples using immunohistochemistry, chromatography and autoradiography. In healed sites, AEA levels were also assessed.ResultsThe number of CBs in inflamed sites of recurrent patients was significantly higher than in those with non‐recurrent disease and also higher than those in healthy subjects. Inflamed sites of recurrent patients had significantly lower CBs receptor activation than those of healthy subjects. Levels of AEA in inflamed sites of non‐recurrent patients were significantly higher than those found both in inflamed recurrent sites and in healthy sites. Otherwise, the amount of AEA in healthy subjects and recurrent inflamed sites was similar. After periodontal therapy, levels of AEA were significantly lower in both periodontal groups. In recurrent sites, they resulted significantly lower than in non‐recurrent and even in healthy subjects.ConclusionsThe endocannabinoid system seems involved differently in subjects with recurrent and non‐recurrent periodontal disease.